EGFR and lung carcinoma: The mPFS following first-line treatment of 11 advanced patients with lung cancer-associated driver gene mutations is 26.6 months, outperforming reported outcomes of three third-generation EGFR-TKIs in the treatment of advanced LC (mPFS: 18.9–20.8 months) [45–47].